Facebook
X
LinkedIn
ForwardNCCN 2026 Oncology Fellows Program: New Horizons in Quality Cancer Care
The NCCN 2026 Oncology Fellows Program: New Horizons in Quality Cancer Care™ is a CME-certified program designed to support oncology fellows in developing the clinical insight, professional competencies, and strategic awareness necessary for success in a dynamic and multidimensional oncology landscape.
Target Audience
This program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.
Learning Objectives
The goal of the NCCN 2026 Oncology Fellows Program is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge, skills, and professional competencies necessary to apply standards of care within their practice and health care settings, while also advancing their development as effective, ethical, and engaged oncology professionals.
Following this program, participants should be able to:
- Apply practical strategies for transitioning into oncology practice, delivering high-quality care across diverse settings, engaging responsibly in social media use, and contributing to global oncology initiatives.
- Integrate evidence-based approaches into clinical decision-making by demonstrating an understanding of current NCCN Guidelines recommendations in the management of cancer-associated venous thromboembolic disease and the NCCN Guidelines development process.
Click here to download the faculty disclosures for the NCCN 2026 Fellows Program.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 5.50 AMA PRA Category 1 Credit™